1428556-50-6

Basic information

• Product Name: benzyl 4-[4-(dimethylcarbamoyl)phenyl]-1,4-diazepane-1-carboxylate
• Synonyms: benzyl 4-[4-(dimethylcarbamoyl)phenyl]-1,4-diazepane-1-carboxylate
• CAS NO: 1428556-50-6
• Molecular Weight: 381.475
• Mol File: 1428556-50-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: benzyl 4-[4-(dimethylcarbamoyl)phenyl]-1,4-diazepane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 4-[4-(dimethylcarbamoyl)phenyl]-1,4-diazepane-1-carboxylate(1428556-50-6)
• EPA Substance Registry System: benzyl 4-[4-(dimethylcarbamoyl)phenyl]-1,4-diazepane-1-carboxylate(1428556-50-6)

Safety Data

• Hazardous Substances Data: 1428556-50-6(Hazardous Substances Data)

Upstream product

• 868066-28-8 benzyl 4-[4-(2,2,2-trifluoroacetyl)phenyl]-1,4-diazepane-1-carboxylate 
• 124-40-3 dimethyl amine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 117009-97-9 benzyl 1,4-diazepane-1-carboxylate 

Downstream Products

• 868066-36-8 4-[4-(3-cyano-2-thioxo-1,2-dihydropyridin-4-yl)-1,4-diazepan-1-yl]-N,N-dimethyl benzamide 
• 868066-26-6 3-amino-4-(4-(4-(dimethylcarbamoyl)phenyl)-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2-carboxamide 
• 868066-34-6 4-(1,4-diazepan-1-yl)-N,N-dimethylbenzamide 

Relevant articles and documents

Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents

A cell-based assay was performed for the discovery of novel bone anabolic agents. Alkaline phosphatase (ALPase) activity of ST2 cells was utilized as an indicator of osteoblastic differentiation, and thienopyridine derivative 1 was identified as a hit compound. 3-Aminothieno[2,3-b]pyridine-2-carboxamide was confirmed to be a necessary core structure for the enhancement of ALPase activity, and then optimization of the C4-substituent on the thienopyridine ring was carried out. Introduction of cyclic amino groups to the C4-position of the thienopyridine ring improved the activity. Especially, N-phenyl-homopiperazine derivatives were found to be strong enhancers of ALPase among this new series. Furthermore, 3-amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2- carboxamide (15k) was orally administered to ovariectomized (OVX) rats over 6 weeks for evaluating the effects on areal bone mineral density (aBMD), and statistically significant improvements in aBMD were observed from the dosage of 10 mg/kg/day.